Lower Glycated Hemoglobin with Real-Time Continuous Glucose Monitoring Than with Intermittently Scanned Continuous Glucose Monitoring After 1 Year: The CORRIDA LIFE Study

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F44555601%3A13430%2F22%3A43897486" target="_blank" >RIV/44555601:13430/22:43897486 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11110/22:10448082

Result on the web

<a href="https://www.liebertpub.com/doi/full/10.1089/dia.2022.0152" target="_blank" >https://www.liebertpub.com/doi/full/10.1089/dia.2022.0152</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1089/dia.2022.0152" target="_blank" >10.1089/dia.2022.0152</a>

Result language

angličtina

Original language name

Lower Glycated Hemoglobin with Real-Time Continuous Glucose Monitoring Than with Intermittently Scanned Continuous Glucose Monitoring After 1 Year: The CORRIDA LIFE Study

Original language description

Background: The aim was to compare the efficacy of real-time continuous glucose monitoring (rtCGM) and intermittently scanned continuous glucose monitoring (isCGM) focusing on glycated hemoglobin (HbA1c) as the primary endpoint.Methods: The CORRIDA LIFE was a 12-month, real-world, nonrandomized study that is part of the CORRIDA clinical trials program. The study compared rtCGM (Dexcom G5 or G6) and isCGM (FreeStyle Libre 14-Day; Abbott) in adults with type 1 diabetes (T1D). Only patients on multiple daily insulin injections or continuous subcutaneous insulin infusion with no automatic functions were included in this study. Primary outcome was the difference in HbA1c between study groups at 12 months.Results: One hundred ninety-one adults with T1D (mean age 40 +/- 13 years, HbA1c 8.1% +/- 3.4% [65 +/- 14 mmol/mol]) participated in this study; 81 patients initiated rtCGM and 110 initiated isCGM. After 12-months, HbA1c was significantly lower with rtCGM versus isCGM (7.1% +/- 3.1% [54.1 +/- 10.1 mmol/mol] vs. 7.7% +/- 3.3% [61.2 +/- 12.2 mmol/mol]), P = 0.0001. The percentage of time in hypoglycemia (&lt;70 mg/dL [&lt;3.9 mmol/L]) was lower among rtCGM vs. isCGM participants [4.3% +/- 2.8% vs. 6.4% +/- 5.3%], P = 0.003). Patients with rtCGM spent less time in clinically significant hypoglycemia (&lt;54 mg/dL [&lt;3.0 mmol/L]) (0.9% +/- 1.0% vs. 2.3% +/- 2.5%, P &lt; 0.0001) and more time in target range (70-180 mg/dL [3.9-10 mmol/L]) than isCGM users (67.5% +/- 14.8% vs. 57.8% +/- 17.0%), P = 0.0002.Conclusions: rtCGM was superior to isCGM in HbA1c, hypoglycemia, and other glycemic outcomes. Our findings provide guidance to clinicians when discussing monitoring options with their patients. The study was registered at www.clinicaltrials.gov (NCT04759495).

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30304 - Public and environmental health

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2022

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

DIABETES TECHNOLOGY &amp; THERAPEUTICS

ISSN

1520-9156

e-ISSN

1557-8593

Volume of the periodical

24

Issue of the periodical within the volume

12

Country of publishing house

US - UNITED STATES

Number of pages

9

Pages from-to

859-867

UT code for WoS article

000892073400001

EID of the result in the Scopus database

—